Elevated RAD51 expression and enhanced HR rates have been observed in many types of cancers, including chronic myelogenous leukemia (CML), in correlation to high proliferation rate and radio- and chemo-resistance (Klein, 2008; Raderschall et al, 2002; Skorski, 2002; Slupianek et al, 2001; Vispe et al, 1998; Xia et al, 1997). Here, RAD51 is linked to cancer.